Today: 29 June 2026
Browse Category

NASDAQ:COGT 10 November 2025 - 14 January 2026

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor, sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival of 16.5 months vs. 9.2 months for sunitinib alone and a 46% objective response rate vs. 26% on sunitinib monotherapy. GlobeNewswire “It is a historic day for Cogent Biosciences and the GIST patient community,” CEO Andrew Robbins said, adding that the bezuclastinib combination “is poised to become the new standard of care” in second‑line GIST. GlobeNewswire
10 November 2025
···

Stock Market Today

  • ASX Penny Stocks: Alligator Energy, Hearts and Minds, Hansen Technologies in Focus
    June 29, 2026, 3:56 PM EDT. Penny stocks on the ASX are grabbing attention as volatility continues. Alligator Energy (ASX:AGE) is still pre-revenue, valued at A$230.73 million, and betting on uranium exploration. The company is running deeper losses but says its cash should last 2.7 years, and analysts see a possible 62.8% jump in shares. Hearts and Minds Investments (ASX:HM1) has a market cap of A$670.92 million. The investment firm's profits are down 84.9%, and its 6.48% dividend yield has investors wondering about longevity. Hansen Technologies sits at a A$904.29 million market cap, pulling in revenue from its Energy & Utilities business. Together, the names show the range of plays and issues in the ASX penny stock scene.
Go toTop